drugset
drugset / Trial / NCT06885021

Evaluate the Safety and Efficacy of HDM1002 Tablets in Chinese Overweight and Obese Adults

NCT06885021 ↗

Phase 3 Not yet recruiting 780 enrolled Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

A Phase 3 Trial to Evaluate the Safety and Efficacy of HDM1002 Tablets in Overweight and Obese Adults

Timeline

Start
2025-03-28
Primary completion
2026-05-30
Completion
2026-06-30

Drugs

EvaluationDrugModalityDoseRoute
Subject HDM1002 Unknown 200 mg Oral
Subject HDM1002 Unknown 400 mg Oral

Indications

No indication recorded.